$55M flows into volatile triple-leveraged biotech ETF despite 5-year losses

Traders poured $54.6 million into the Direxion Daily S&P Biotech Bull 3X ETF (LABU) on October 14, 2026, marking the largest inflow relative to its $597 million size. LABU offers triple daily exposure to biotech stocks, making it highly volatile and suitable only for short-term trading due to daily rebalancing and volatility decay. Despite a 42.76% gain in the unleveraged biotech ETF XBI over one year, LABU returned 107.58%, but over five years LABU lost 79.14% while XBI gained 20.23%, showing the risks of holding leveraged ETFs long-term. The inflow signals short-term trader interest after a recent pullback but does not indicate long-term confidence in biotech stocks.

The biotech ETF XBI trades at USD 147.55 on Pluang as of Oct 20, 2026 16:01 WIB, down 0.23% in one day. Its market cap is $10.35 billion with a 52-week high of $169.55 and low of $107.32. Pluang users hold XBI for an average of 40 days, showing moderate-term interest despite recent volatility.